bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: N O S A J J M A M F J
2013: D N

  No-Fridge Nasal Vaccines on the Horizon
Tests in mice look promising for people in remote regions, researcher says

By Robert Preidt

WEDNESDAY, March 19, 2014 (HealthDay News) -- Nasal-spray vaccines that don't require refrigeration -- which are still in the experimental stage -- could help protect people in remote regions from future disease outbreaks, according to a researcher.

Most current vaccines require needles, refrigeration and booster shots, which can complicate their use. Refrigeration isn't available in some poor areas of the world, which means many people most in need of vaccinations aren't getting them.

New, easy-to-use vaccines are being developed that don't need to be kept cold, a researcher said at an American Chemical Society meeting this week in Dallas.

"Our nanovaccines can be stored at room temperature for as long as six to 10 months and still work," Balaji Narasimhan, a professor of chemical engineering at Iowa State University, said in a society news release.

"Also, we're designing them so they get delivered in one dose through a nasal spray, which could potentially allow patients to give the vaccine to themselves," said Narasimhan, the project's lead researcher.

The new nanovaccines affect a different part of the immune system than current vaccines. They could also prove more effective in fighting emerging and re-emerging diseases, such as whooping cough, according to the news release.

They have been shown to be effective in rodents, and the researchers are moving on to tests in larger animals, Narasimhan said. Experts note, however, that results achieved in animal studies often aren't able to be replicated in humans.

"Our nanovaccine approach could be instrumental for containing future outbreaks of recently emerged and re-emerging diseases, such as SARS, new flu strains and multi-drug-resistant tuberculosis," Narasimhan said.

Data and conclusions presented at meetings typically are considered preliminary until published in a peer-reviewed medical journal.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about vaccines.

SOURCE: American Chemical Society, news release, March 19, 2014

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=685870

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Research Personnel
Affect
Hypersensitivity
Lead
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact